Forward Citations = 555

Loading Chart...

3 inventors (with patents filed for the assignee):

Rajendra Kumar Joshi (8 out of 24 patents)

Hans-Peter Strebel (7 out of 18 patents)

Hans Peter Strebel (1 out of 1 patent)

8 patents: Sort by Forward Citations

1. 7320999 - Dimethyl fumarate for the treatment of multiple sclerosis (2008-01-22),

2. 7157423 - Fumaric acid amides (2007-01-02),

3. 6858750 - Use of fumaric acid derivatives for treating mitochondrial diseases (2005-02-22),

4. 6509376 - Utilization of dialkyfumarates (2003-01-21),

5. 6436992 - Use of fumaric acid derivatives (2002-08-20),

6. 6359003 - Use of fumaric acid derivatives in transplant medicine (2002-03-19),

7. 6355676 - Fumaric acid micro tablets (2002-03-12),

8. 6277882 - Utilization of alkyl hydrogen fumarates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis (2001-08-21),

Company Overview

Fumapharm Ag is a biotech company specializing in the development of innovative treatments for rare diseases. With a focus on fumaric acid esters, the company is dedicated to improving the quality of life for patients worldwide. Fumapharm Ag is committed to research and development to bring new therapies to market and make a positive impact in the medical field.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

8 Patents

#16 in Lucerne

#1,223 in Switzerland

Lucerne, Switzerland

Fumapharm Ag

Forward Citations = 555

3 inventors:

Rajendra Kumar Joshi (8 out of 24 patents)

Hans-Peter Strebel (7 out of 18 patents)

Hans Peter Strebel (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Fumapharm Ag. Retrieved from https://idiyas.com/company/fumapharm-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]